New technologies for nephron-sparing surgery in upper urinary tract cancers.

PURPOSE OF REVIEW Nephron-sparing surgery (NSS) is the preferred treatment in patients with low-risk upper tract urothelial carcinoma (UTUC). Improving both instruments and topical chemotherapy regimens efficacy is crucial to achieve better outcomes. The purpose of this review is to summarize the most recent evidence on technological advances for the conservative management of UTUC with implications on diagnosis and treatment. RECENT FINDINGS Novel diagnostic tools, lasers, and topical chemotherapy systems delivery have been implemented to optimize NSS outcomes for UTUC. SUMMARY Photodynamic ureteroscopy has been reported to improve cancer detection rate as compared with conventional imaging or ureteroscopy, especially in case of carcinoma in situ. However, refinements in photosensitizer administration and dedicated instruments are needed. The armamentarium of lasers for UTUC ablation is composed of several devices with peculiar characteristics. Together with Ho:YAG and Tm:YAG lasers, the Thulium Fiber Laser (TFL) is gaining momentum in UTUC ablation. Strengths and weaknesses of each laser must be considered to maximize oncological and safety outcomes. Several novel endocavitary chemotherapy delivery systems have been tested to reduce tumor recurrence and progression after NSS. Administration of gel-based chemotherapeutic agents has been proven to be effective in humans; conversely, drug-eluting ureteral stent systems are still conceptual.

[1]  F. Algaba,et al.  Long-term Oncologic Outcomes of Endoscopic Management of High-risk Upper Tract Urothelial Carcinoma: The Fundació Puigvert's Experience. , 2023, Journal of endourology.

[2]  J. Huguet,et al.  Manejo del carcinoma in situ de tramo urinario superior diagnosticado por biopsia ureteroscópica: ¿es el bacilo de Calmette-Guérin una alternativa a la nefroureterectomía? , 2023, Actas Urológicas Españolas.

[3]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. , 2023, European urology.

[4]  S. Shariat,et al.  A Review of How Lasers Are Used in UTUC Surgery: Can the Choice of Laser Affect Outcomes? , 2023, Cancers.

[5]  F. Sánchez-Margallo,et al.  Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma. , 2023, Minerva urology and nephrology.

[6]  Y. Lotan,et al.  Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma , 2023, The Journal of urology.

[7]  S. Di Pietro,et al.  Effectiveness and Safety of Thulium Fiber Laser in the Conservative Management of Patients with Upper Tract Urothelial Carcinoma , 2022, European urology open science.

[8]  M. Humphreys,et al.  Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi‐institutional retrospective cohort study , 2022, BJU international.

[9]  F. Sánchez-Margallo,et al.  Cytotoxicity Assessment of a New Design for a Biodegradable Ureteral Mitomycin Drug-Eluting Stent in Urothelial Carcinoma Cell Culture , 2022, Polymers.

[10]  S. Aznar-Cervantes,et al.  Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study , 2022, Polymers.

[11]  S. Anai,et al.  A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial , 2022, Contemporary clinical trials communications.

[12]  Katie S. Murray,et al.  Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience , 2022, The Journal of urology.

[13]  D. Lifshitz,et al.  Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report , 2021, The Journal of urology.

[14]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[15]  A. Breda,et al.  Endoscopic management of upper urinary tract urothelial carcinoma: oncologic outcomes and prognostic factors in a contemporary cohort. , 2021, Journal of endourology.

[16]  B. Eisner,et al.  Conservative treatment of upper urinary tract carcinoma in patients with imperative indications , 2021 .

[17]  T. Matsuda,et al.  Photodynamic Diagnosis–guided Dual Laser Ablation for Upper Urinary Tract Carcinoma: Preoperative Preparation, Surgical Technique, and Clinical Outcomes , 2021, European urology open science.

[18]  A. Shabsigh,et al.  Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma , 2021, Cancer Chemotherapy and Pharmacology.

[19]  A. Gözen,et al.  Thulium-laser retrograde intra renal ablation of upper urinary tract transitional cell carcinoma: an ESUT Study , 2021 .

[20]  Masami Watanabe,et al.  Photodynamic diagnostic ureteroscopy using the VISERA ELITE video system for diagnosis of upper-urinary tract urothelial carcinoma: a prospective cohort pilot study , 2021, BMC Urology.

[21]  M. Gleave,et al.  A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. , 2020, Urologic oncology.

[22]  E. Emiliani,et al.  The Impact of Ureteroscopy following Computed Tomography Urography in the Management of Upper Tract Urothelial Carcinoma. , 2020, The Journal of urology.

[23]  A. Breda,et al.  Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  D. Lifshitz,et al.  Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. , 2020, The Lancet. Oncology.

[25]  B. Becker,et al.  Comparative analysis of vaporization and coagulation properties of a hybrid laser (combination of a thulium and blue diode laser) vs. thulium and Ho:YAG lasers: potential applications in endoscopic enucleation of the prostate (EEP). , 2020, Journal of endourology.

[26]  F. Regis,et al.  Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial. , 2020, Journal of endourology.

[27]  M. Furihata,et al.  5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼. , 2019, Photodiagnosis and photodynamic therapy.

[28]  B. Becker,et al.  Effect of optical fiber diameter and laser emission mode (cw vs pulse) on tissue damage profile using 1.94 µm Tm:fiber lasers in a porcine kidney model , 2019, World Journal of Urology.

[29]  S. Shariat,et al.  Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis , 2019, World Journal of Urology.

[30]  A. Breda,et al.  Comparison of biopsy devices in upper tract urothelial carcinoma , 2018, World Journal of Urology.

[31]  E. Messing,et al.  Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial , 2018, JAMA.

[32]  C. Wood,et al.  Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. , 2017, Journal of endourology.

[33]  Elsawi Osman,et al.  Photodynamic diagnosis in upper urinary tract urothelial carcinoma: A systematic review , 2017, Arab journal of urology.

[34]  V. Margulis,et al.  Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma , 2017, World Journal of Urology.

[35]  M. Babjuk,et al.  Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. , 2016, European urology.

[36]  R. Reis,et al.  Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer. , 2016, International journal of pharmaceutics.

[37]  A. Abbruzzese,et al.  Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Lenis,et al.  Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. , 2017, Urology.